Abstract
When evaluating the effectiveness of the drug Mefloquine against SARS-Cov-2 coronavirus, in vitro experiments examined its toxicity for African green monkey kidney cell culture - Vero C1008, as well as antiviral activity against SARS-Cov-2, which was evaluated by suppressing the cytopathic effect the virus. A study of the toxicity of the drug Mefloquine showed that the concentration at which the drug exerts a cytopathic effect against 50% of Vero C1008 cells is 4.5 μg / ml. The maximum tolerated concentration (MTD) of Mefloquine is 2.25 μg / ml. A study of the effectiveness showed that 1 day after infection, the antiviral effect of Mefloquine was recorded when the drug was added 24 hours and 1 hour before infection with SARS-CoV-2, as well as when it was added 1 hour after infection, the cell culture was already at a concentration of 0.5 μg / ml Mefloquine at a concentration of 2 μg / ml, added to the Vero C1008 cell culture 1 hour after the introduction of SARS-CoV-2, completely blocked the action of the virus for 2 days after infection.
Highlights
When evaluating the effectiveness of the drug Mefloquine against severe acute respiratory syndrome (SARS)-CoV-2 coronavirus, in vitro experiments examined its toxicity for African green monkey kidney cell culture — Vero C1008, as well as antiviral activity against SARS-CoV-2, which was evaluated by suppressing the cytopathic effect the virus
Until 2002, coronaviruses were regarded as pathogens causing upper respiratory tract (URT) diseases that extremely rarely ended in death
The studied Mefloquine lines were introduced into tubes containing Vero C1008 cell monolayer and incubated at 37.0 ± 0.5 °C for 120 hours
Summary
EXPERIMENTAL EVALUATION OF THE ACTIVITY OF THE PRODUCT MEFLOCHINE AGAINST CORONAVIRUS SАRS-COV-2. When evaluating the effectiveness of the drug Mefloquine against SARS-CoV-2 coronavirus, in vitro experiments examined its toxicity for African green monkey kidney cell culture — Vero C1008, as well as antiviral activity against SARS-CoV-2, which was evaluated by suppressing the cytopathic effect the virus. There are four coronaviruses (HCoV-229E, -OS43, -NL63 and -HKU1) known to circulate year-round and cause acute respiratory viral infections. At the end of 2002, the SARS-CoV coronavirus was registered It is the causative agent of SARS, severe acute respiratory syndrome. During this epidemic, over 8000 cases were registered in 37 countries, of which 774 were fatal. The causative agent of this disease is SARS-CoV-2, a new coronavirus. Its viral replication suppression EC50 was 0.306 ± 0.091 μM
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
